
Warning shots have been fired by both the General Medical Council (GMC) and the Labour Party about the recruitment issues …

Novartis has got its wallet out to pick up a Priority Review Voucher (PRV) from Ultragenyx, forking out $130 million …

With access to rare disease treatments coming under increasing attention, both in the EU and the US, Pharmafile.com took the …

Pfizer has revealed that the FDA has passed marketing approval for Xeljanz (tofacitinib) for the treatment of active psoriatic arthritis …

Apotex, the world’s seventh largest generics manufacturer, has lost its Chairman and founder, after Barry Sherman and his wife, Honey, …

Boehringer Ingelheim is set to part ways with its Chief Financial Officer Simone Menne after 16 months due to fundamental …

There was a time when PD-1/L1 immunotherapy treatments could do no wrong, blasting through indication after indication. However, the limits …

Tesaro’s Zejula has been launched in the UK but availability on the NHS has still not been decided. The PARP …

Cancer Research UK has announced that its subsidiary, Cancer Research Technology (CRT), and Celgene have agreed a drug discovery collaboration. …

Just 10 days away from Christmas, and big news is still flowing in the industry. Sanofi remains embroiled in scandal …

When Kare Shultz decided to take on the CEO position at Teva he would have known that he was setting …

Novartis has announced that the President of its oncology business, Bruno Strigini, is to retire next year, citing personal reasons …

Bristol-Myers Squibb has once again struck a deal with Ono Pharmaceutical for multiple programs, seeking to discover a boost to …

Novartis, Abbott, Emcure Pharma and USV have become the targets of an investigation by the Competition Commission of India (CCI) …

Pharmafile.com sat down with Dr Rav Seeruthun, Medical Director of Roche UK, to discuss his career thus far and the lessons …

The fight against the growth of antibiotic resistance has become a major talking point internationally in recent years and the …

A team of clinical researchers at Barts Health NHS Trust and Queen Mary University of London have reported that a …

Pfizer is now in the unusual position of owning two biosimilars to Johnson & Johnson’s Remicade, though one of these …

Daiichi Sankyo had a busy day in terms of its deals in oncology, not only did it tear up its …

Shortly following its announcement of Philippe Mazas as Chief Information Officer, Mundipharma has revealed it has appointed Alberto Martinez as …